Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Study ID
DAIT ASC01

Cancer Related
No

Healthy Volunteers
No

Study Sites

  • Clements University Hospital

Contact
Adetoun Sodimu
214/645-6493
adetoun.sodimu@utsouthwestern.edu

Principal Investigator
Fernando Torres, M.D.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Brief Overview


Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious,
life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the
connective tissue characterized by scarring (fibrosis) and atrophy of the skin, joints and
tendons, skeletal muscles, and internal organs, and immunological disturbances. One-year
survival for patients with SSc-PAH ranges from 50-81%. There is currently no cure for
SSc-PAH and treatment is limited to vasodilator therapy used in all forms of PAH. In recent
studies, immunotherapy was shown to be effective in treating SSc-interstitial lung disease,
another serious, life-threatening manifestation of SSc. In addition, there are compelling
pre-clinical data and anecdotal clinical reports that suggest modulation of the immune
system may be an effective strategy for treating SSc-PAH. To test this approach, this trial
will determine if rituximab, an immunotherapy, has a marked beneficial effect on clinical
disease progression, with minimal toxicity, in patients with SSc-PAH when compared to
placebo.

Summary


This prospective, double-blind, placebo-controlled, multi-center, randomized trial will
evaluate the effect of rituximab on disease progression in subjects with SSc-PAH receiving
concurrent stable-dose standard medical therapy with a prostanoid, endothelin receptor
antagonist, and/or phosphodiesterase 5 (PDE-5) inhibitor. The study will focus on assessment
of clinical response and safety measures longitudinally. In addition, the effects of
treatment with rituximab on the underlying immune mechanisms associated with B-cell
dysregulation and pathogenic autoantibody response in this disease will be investigated.
1000 mg of rituximab or placebo will be administered as two IV infusions given two weeks
apart. Clinical assessments and sample collection will occur at monthly visits through Week
48. If a participant has not recovered B cells by Week 48, B cell studies will be conducted
quarterly until reconstitution is documented or for 2 years after initial treatment.

This trial will include a sub-study, entitled "Right Ventricular Response to Rituximab in
Systemic Sclerosis-Associated Pulmonary Arterial Hypertension - A Magnetic Resonance Imaging
Sub-study" (RESTORE Sub-study). The objective of the RESTORE sub-study is to evaluate the
therapeutic effect of rituximab on the right ventricle of patients with SSc-PAH. Changes in
right ventricular end diastolic volume index (RVEDVI) and stroke volume (SV) determined by
cardiac MRI will be used as surrogates of right ventricle function and prognosis. Enrollment
for the RESTORE sub-study will parallel that of main trial. Twenty patients from each
treatment arm, distributed among all participating sites, will be recruited for this
sub-study. Each patient will be studied at baseline (i.e. prior to initiation of study drug)
and after 24 weeks or at time of discontinuation. In addition to the data collection and
testing specified in the main trial, participants in RESTORE will undergo comprehensive
cardiac MRI evaluation. All main trial study inclusion and exclusion criteria apply, as well
as additional exclusion criteria that pertain only to the RESTORE sub-study: 1) known
hypersensitivity to Gadolinium; 2) inability to tolerate or cooperate with MRI; 3) morbid
obesity; and 4) presence of metallic objects or pacemakers.

Participant Eligibility


Inclusion Criteria:

- Subject has provided written informed consent.

- Subject must be between the ages of 18 and 75.

- Clinical diagnosis of systemic sclerosis (either limited or diffuse cutaneous
disease).

- Diagnosis of SSc-PAH within the past 5 years, with a mean pulmonary arterial pressure
of ≥ 25 mmHg at entry.

- Mean Pulmonary Vascular Resistance (PVR) of > 3 Wood units.

- Screening 6-minute Walking Distance (6MWD) of at least 100 meters.

- New York Heart Association (NYHA) Functional Class II, III, or IV.

- Subject must be able to maintain O2 saturation ≥ 90% at rest (with or without
oxygen). Oxygen use is permitted.

- Subject must be vaccinated with the pneumococcal vaccine at least one month prior to
initiation of therapy, unless subject was vaccinated within 5 years of study entry.

- Subject must have been treated with background medical therapy for PAH (prostanoid,
endothelin receptor antagonist, PDE-5 inhibitor, and/or guanylate cyclase
stimulators) for a minimum of 8 weeks and have been on stable dose medical therapy
for at least 4 weeks prior to randomization with no expectation of change for 24
weeks after randomization.

Exclusion Criteria:

- Documented PAH for greater than 5 years at the time of randomization defined as:

- Measurement of a mean Pulmonary Artery Pressure (PAP) > 25 mmHg by right heart
catheterization at least 5 years previously, OR

- Treatment with targeted background PAH therapy for > 5 years.

- Pulmonary Capillary Wedge Pressure > 15 mmHg or Left Ventricular End Diastolic
Pressure > 15 mmHg.

- Persistent hypotension with Systolic Blood Pressure (SBP) < 90 mmHg.

- Treatment with cyclophosphamide within 4 weeks of randomization.

- Treatment with immunocompromising biologic agents within 4 weeks prior to treatment
initiation or treatment with infliximab within 8 weeks prior to treatment initiation.

- If being treated with a non-biologic immunosuppressive or immunomodulating drug,
changes in dosage within 4 weeks prior to randomization. Subjects taking prednisone
or equivalent corticosteroid > 10mg daily are excluded.

- Previous exposure to any lymphocyte or B cell depleting agent.

- PAH for any reason other than SSc.

- History of coronary artery disease, significant ventricular tachy-arrhythmia, stent
placement, coronary artery bypass surgery, and/or myocardial infarction.

- Moderate or severe interstitial lung disease.

- Chronic infections.

- Positive serology for infection with hepatitis B or C.

- A deep space infection within the past 2 years.

- Evidence of active infection within 2 weeks of randomization

- Presence of a positive tuberculosis (TB) skin test (e.g., PPD test) or positive
QuantiFERON®-TB blood test, an indeterminate QuantiFERON®-TB blood test, or latent
tuberculosis (TB).

- Significant renal insufficiency.

- Active, untreated SSc renal crisis at the time of enrollment.

- Recent administration of a live vaccine (< 8 weeks) or any other immunization within
4 weeks of treatment.

- History of anaphylaxis or IgE-mediated hypersensitivity to murine proteins or any
component of rituximab.

- Pregnancy.

- Lactation.

- History of malignancy within the last 5 years, except for resected basal or squamous
cell carcinoma, treated cervical dysplasia, or treated in situ cervical cancer Grade
I.

- A woman of childbearing potential who is unwilling to use a medically acceptable form
of birth control

- History of non-compliance with other medical therapies.

- History of alcohol or drug abuse within 1 year of randomization.

- Receipt of any investigational drug or device within 4 weeks before the Screening
Visit, with the exception of investigational prostanoids, endothelin receptor
antagonists, and PDE-5 inhibitors, and guanylate cyclase stimulators.

- Recipient of lung transplant.

- Laboratory parameters at the screening visit showing any of the following abnormal
results: Transaminases > 2x the upper limit of normal (ULN) and/or bilirubin > 2x
ULN; Absolute neutrophil count < 1,500/mm3; Platelet count < 100,000/mm3; Hemoglobin
< 9 g/dL.

- Concurrent treatment in a clinical research study using a non-FDA approved agent with
the exception of an open-label study/study extension of investigational prostanoids,
endothelin receptor antagonists, and PDE-5 inhibitors, and guanylate cyclase
stimulators, provided the open-label investigational drug will be available and dose
will remain stable through the trial's primary outcome time point of 24 weeks after
randomization in this study, ASC01 (NCT01086540).

- Any condition or treatment, which in the opinion of the investigator, places the
subject at unacceptable risk as a participant in the trial.